nebicapone + levodopa + carbidopa

This drug is a **combination of nebicapone (BIA 3-202), levodopa, and carbidopa**. Nebicapone is a novel, peripherally acting catechol-O-methyltransferase (COMT) inhibitor developed to increase levodopa bioavailability and decrease conversion to 3-O-methyldopa. Levodopa is a dopamine precursor and the primary treatment for Parkinson’s disease, while carbidopa is a dopa decarboxylase inhibitor that prevents peripheral conversion of levodopa to dopamine, increasing the amount available to the brain. This combination aims to optimize the pharmacokinetics and therapeutic effect of levodopa in Parkinson’s disease by inhibiting two major peripheral metabolic pathways (COMT and dopa decarboxylase)[1][2][3][4][5][6][7]. Nebicapone was developed primarily by BIAL for use as a levodopa-sparing agent in Parkinson’s disease.

Other names

nebicapone + levodopa + carbidopaBIA 3-202 + levodopa + carbidopa